Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-01

Study Completion Date

2025-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission.

Pharmacological treatment is given to prevent development of cardiac and gastrointestinal sequelae. There are two available drugs for this disease; Nifurtimox and Benznidazole. They both has proven efficacy for acute face treatment, with different security profiles. There are not enough adequate studies comparing both drugs made in a large number of subjects. Investigators will study 900 patients treated with both drugs and compare security and efficacy in a retrospective cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease

NCT04897516

Chagas Disease

RECRUITING PHASE3

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

NCT00123916

Chagas Disease Trypanosomiasis Heart Disease

COMPLETED PHASE3

Study of Nitazoxanide in the Treatment of Amebiasis in Children

NCT00366730

Amebiasis

COMPLETED PHASE3

Treatment of Asymptomatic Toxocariasis With Albendazole in Children

NCT00755560

Toxocariasis

UNKNOWN PHASE3

Efficacy of Racecadotril in Acute Watery Diarrhea in Children

NCT01577043

Acute Diarrhea Acute Gastroenteritis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chagas Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nifurtimox

Patients treated with Nifurtimox from 1984 to 2017

Clinical Manifestations

Intervention Type OTHER

Clinical manifestations in patients treated with Nifurtimox and Benznidazole

Serologic response

Intervention Type DIAGNOSTIC_TEST

Serologic response in patients treated with Nifurtimox and Benznidazole

Direct method

Intervention Type DIAGNOSTIC_TEST

Direct method tests in patients treated with Nifurtimox and Benznidazole

Adverse events

Intervention Type BEHAVIORAL

Adverse events in patients treated with Nifurtimox and Benznidazole

Benznidazole

Patients treated with Benznidazole from 1984 to 2017

Clinical Manifestations

Intervention Type OTHER

Clinical manifestations in patients treated with Nifurtimox and Benznidazole

Serologic response

Intervention Type DIAGNOSTIC_TEST

Serologic response in patients treated with Nifurtimox and Benznidazole

Direct method

Intervention Type DIAGNOSTIC_TEST

Direct method tests in patients treated with Nifurtimox and Benznidazole

Adverse events

Intervention Type BEHAVIORAL

Adverse events in patients treated with Nifurtimox and Benznidazole

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical Manifestations

Clinical manifestations in patients treated with Nifurtimox and Benznidazole

Intervention Type OTHER

Serologic response

Serologic response in patients treated with Nifurtimox and Benznidazole

Intervention Type DIAGNOSTIC_TEST

Direct method

Direct method tests in patients treated with Nifurtimox and Benznidazole

Intervention Type DIAGNOSTIC_TEST

Adverse events

Adverse events in patients treated with Nifurtimox and Benznidazole

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients between 0 and 18 years of age with confirmed Chagas disease (defined as patients under 8 months with positive parasitemia or older with 2 positive different techniques for serology) that received treatment with Nifurtimox or Benznidazole.